v3.20.2
Identifiable Intangible Assets and Goodwill
 9 Months Ended
Sep. 27, 2020
Goodwill and Intangible Assets Disclosure [Abstract]  
Identifiable Intangible Assets and Goodwill Identifiable Intangible Assets and Goodwill
A. Identifiable Intangible Assets

Balance Sheet Information
The following summarizes the components of Identifiable intangible assets:
 September 27, 2020December 31, 2019
(MILLIONS OF DOLLARS)Gross
Carrying
Amount		Accumulated
Amortization		Identifiable
Intangible
Assets, less
Accumulated
Amortization		Gross
Carrying
Amount		Accumulated
Amortization		Identifiable
Intangible
Assets, less
Accumulated
Amortization
Finite-lived intangible assets
Developed technology rights(a)
$90,052 $(66,212)$23,840 $88,730 $(63,106)$25,625 
Brands922 (766)156 922 (741)181 
Licensing agreements and other(b)
2,385 (1,238)1,146 1,772 (1,191)582 
93,358 (68,216)25,142 91,425 (65,037)26,387 
Indefinite-lived intangible assets
Brands1,991 1,991 1,991 1,991 
IPR&D(c)
3,221 3,221 5,919 5,919 
Licensing agreements and other(b)
573 573 1,073 1,073 
5,785 5,785 8,983 8,983 
Identifiable intangible assets(d)
$99,143 $(68,216)$30,927 $100,408 $(65,037)$35,370 
(a)The change in the gross carrying amount primarily reflect the transfer of $600 million from IPR&D to Developed technology rights to reflect the approval of Braftovi in combination with Erbitux® (cetuximab), for the treatment of BRAFV600E-mutant metastatic colorectal cancer after prior therapy and a $200 million measurement period adjustment related to the acquisition of Array (see Note 2A).
(b)The changes in the gross carrying amounts primarily reflect the transfer of $600 million from Indefinite-lived Licensing agreements and other to finite-lived Licensing agreements and other to reflect the approval in the U.S. of several products subject to out-licensing arrangements acquired from Array, as well as measurement period adjustments related to the acquisition of Array.
(c)The changes in the gross carrying amount primarily reflect a $1.2 billion measurement period adjustment related to the acquisition of Array, a $900 million impairment of IPR&D (see Note 4), and the transfer of $600 million from IPR&D to Developed technology rights to reflect the approval of Braftovi in combination with Erbitux® (cetuximab), for the treatment of BRAFV600E-mutant metastatic colorectal cancer after prior therapy.
(d)The decrease is primarily due to amortization, the $900 million impairment of IPR&D, and measurement period adjustments related to the acquisition of Array.
Our identifiable intangible assets are associated with the following, as a percentage of total identifiable intangible assets, less accumulated amortization:
September 27, 2020
BiopharmaUpjohnWRDM
Developed technology rights99 %1 %— 
Brands, finite-lived100 %— — 
Brands, indefinite-lived42 %58 %— 
IPR&D92 %— 8 %
Licensing agreements and other, finite-lived99 %1 %1 %
Licensing agreements and other, indefinite-lived100 %— — 

Amortization
Total amortization of finite-lived intangible assets was $910 million for the third quarter of 2020 and $1.2 billion for the third quarter of 2019, and $2.7 billion for the first nine months of 2020 and $3.6 billion for the first nine months of 2019.
B. Goodwill
The following summarizes the components and changes in the carrying amount of Goodwill:
(MILLIONS OF DOLLARS)BiopharmaUpjohnTotal
Balance, December 31, 2019$48,202 $10,451 $58,653 
Additions(a)
727 — 727 
Other(b)
420 102 522 
Balance, September 27, 2020$49,349 $10,553 $59,902 
(a)Additions primarily represents the impact of measurement period adjustments related to our Array acquisition (see Note 2A).
(b)Represents the impact of foreign exchange.